Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations.

EJC Skin Cancer · 2025 · PMC7618636 · PMID 41550533

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Within the Relativity 047 study, nivolumab-relatlimab showed a trend towards improved PFS over nivolumab (HR, 0.63 (95 % CI, 0.32–1.22)), but no benefit in OS (HR 1.05 (95 % CI, 0.55–2.00) or ORR (34.8 % vs 25.0 %) [ 3 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.